![Satyavrat Shukla](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Satyavrat Shukla
Keine laufenden Positionen mehr
Vermögen: 99 149 $ am 31.08.2026
Profil
Satyavrat Shukla worked at Cornerstone Research, Inc. as Principal from 2003 to 2012.
Then worked at Vertex Pharmaceuticals, Inc. as Vice President & Global Head-Corporate Finance from 2012 to 2019.
Worked at Alaunos Therapeutics, Inc. as Chief Financial Officer & Executive Vice President from 2019 to 2020.
Worked at Spero Therapeutics, Inc. as Director in 2025.
Education includes an undergraduate degree from Harvard University in 1993 and an MBA from Yale University in 1999.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SPERO THERAPEUTICS, INC. 0,14 % | 01.04.2026 | 81 270 ( 0,14 % ) | 99 149 $ | 31.08.2026 |
Ehemalige bekannte Positionen von Satyavrat Shukla
| Unternehmen | Position | Ende |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Vorstandsvorsitzender | 10.01.2025 |
| ALAUNOS THERAPEUTICS, INC. | Finanzdirektor/CFO | 31.12.2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.07.2019 |
Cornerstone Research, Inc.
 Cornerstone Research, Inc. Miscellaneous Commercial ServicesCommercial Services Provides testimony, economic and financial analysis to attorneys | Corporate Officer/Principal | 01.01.2012 |
Ausbildung von Satyavrat Shukla
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornerstone Research, Inc.
Cornerstone Research, Inc. Miscellaneous Commercial ServicesCommercial Services Provides testimony, economic and financial analysis to attorneys | Commercial Services |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
